Phase 1
Completed N=24
Carvedilol (25 mg) in 24 Fed, Healthy, Adult Subjects
Healthy
Source: ClinicalTrials.gov NCT00834873 ↗
Enrolled (actual)
24
Serious AEs
—
Results posted
Aug 2009
Primary outcomePrimary: Cmax - Maximum Observed Concentration - Carvedilol in Plasma — 89.91; 97.05 ng/mL
Summary
The objective of this randomized, single-dose, two-way crossover evaluation is to compare the relative bioequivalence of a test carvedilol formulation (TEVA Pharmaceuticals USA) to and equivalent oral dose of the commercially available carvedilol (COREG®, SmithKline Beecham Pharmaceuticals) in a test population of 24 adult individuals under fed conditions.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cmax - Maximum Observed Concentration - Carvedilol in Plasma |
89.91; 97.05 | — |
| PRIMARY AUC0-inf - Area Under the Concentration-time Curve From Time Zero to Infinity (Extrapolated) - Carvedilol in Plasma |
467.57; 490.16 | — |
| PRIMARY AUC0-t - Area Under the Concentration-time Curve From Time Zero to Time of Last Non-zero Concentration (Per Participant) - Carvedilol in Plasma |
455.91; 478.61 | — |
Eligibility Criteria
Inclusion Criteria
- Sex: Male of Female; similar proportions of each preferred.
- Age: At least 18 years.
- Weight: Minimum of 120 pounds and a BMI (body mass index) of less than 30.
Exclusion Criteria
- Subjects not complying with the above inclusion criteria must be excluded from the study.
- In addition, any one of the conditions listed below will exclude a subject from the study.
- History of treatment for alcoholism, substance abuse, or drug abuse within the past 24 months
- History of malignancy, stroke, diabetes, cardiac, renal or liver disease, or other serious illness.
- History of treatment for any gastrointestinal disorder within the past five (5) years.
- History of, or presence of, asthma
- History of peripheral vascular disease
- History of heart failure
- History of pre-existing cardiac arrythmias associated with tachycardia
- History of severe sensitivity to allergens, requiring urgent medical treatment.
- Females who are pregnant or lactating
- History of hypersensitivity to carvedilol, or any beta adrenergic blocking drug.
- Conditions upon screening which might contraindicate or require that caution be used in the administration of carvedilol, including:
- sitting systolic blood pressure below 100 mmHg, or diastolic pressure below 60 mmHg.
- Heart rate less than 60 beats per minute after a 5-minute rest in a seated position.
- Inability to read and/or sign the consent form.
- Treatment with any other investigational drug during the four (4) weeks prior to the initial dosing for this study.
- Subjects who smoke or use tobacco products or are currently using nicotine products (patches, gums,etc.) Ninety (90) days abstinence is required.
- subjects who have donated blood within four (4) weeks prior to the initial dosing for this study.
Data sourced from ClinicalTrials.gov (NCT00834873). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.